Compounding pharmacies face ingredient shortages
70 HP 130 AOD-9604 HGH Fragment 176-191 Lipolytic ALIASES AOD-9604, AOD9604, hGH(176-191), Tyr-hGH(177-191) CLASS Synthetic growth-hormone C-terminal fragment lipolytic candidate FORMULA CHNOS SEQUENCE 16-residue fragment corresponding to hGH(177-191) with N-terminal Tyrosine addition HALF-LIFE Short (minutes) plasma ROUTES Subcutaneous (Phase 2 obesity) Oral (food-supplement contexts in some jurisdictions) MECHANISM OF ACTION Synthetic 15-amino-acid fragment of human growth hormone (residues 176-191)
Some community references use "KLOW 80mg" as a shorthand for the standard product specification
Region-specific changes in presynaptic agmatine and glutamate levels in the aged rat brain
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al